MINERVA LABS

1203 S WHITE CHAPEL SUITE 150
SOUTHLAKE, TEXAS 76092
Phone: +1 965-279-2091
EMAIL: INFO@MINERVALABS.HEALTH
WEBSITE: WWW.MINERVALABS.HEALTH

HEREDITARY THYROID DISORDERS RISK TESTING REQUISITION FORM

INSTRUCTIONS

- Patient and Physician must sign the consent form
- All items identified as '***Required***' must be provided/attached to the requisition form.

SUBMISSION CHECKLIST

- ☐ SOAP notes and progress notes
- ☐ Patient insurance ID card or face sheet
- ☐ Physician and Patient Signature

Ordering Physician Information

Physician Name	NPI#	FAX#
Office/Practice/Institution Name	Physician's Email	
Street Address		
City	State	Zip Code
Office Contact Name	Contact Phone	Contact Email

Ordering Provider (Please select one physician per order)

Physician name: ..... Physician NPI: ..... Physician name: ..... Physician NPI: .....

Physician name: ..... Physician NPI: ..... Physician name: ..... Physician NPI: .....

PATIENT INFORMATION

REQUIRED

Patient First Name	Patient Last Name	Date of Birth (mm/dd/yyyy)	Phone Number
Address	City	State	Zip

Gender Identity

- ☐ Male
- ☐ Female
- ☐ Female-to-Male
- ☐ Male-to-Female
- ☐ Genderqueer
- ☐ Other (Specify) .....
- ☐ Choose not to Disclose

Sexual Orientation

- ☐ Lesbian, gay, or homosexual
- ☐ Straight or heterosexual
- ☐ Bisexual
- ☐ Something else (Describe) .....
- ☐ Choose not to disclose

Ancestry

- ☐ White/Caucasian
- ☐ Native American
- ☐ Hispanic
- ☐ African American
- ☐ Ashkenazi Jewish
- ☐ Middle Eastern
- ☐ American Indian
- ☐ Asian
- ☐ Native Hawaiian and Other Pacific Islander

PAYMENT OPTIONS (SELECT ONE)

REQUIRED

- ☐ Insurance Billing (Please provide the insurance information)
- ☐ Self-Pay (Please provide credit card details or mail the check to the laboratory address)
- ☐ Client Billing / Institutional Billing

Primary Insurance	Insurance Policy/ID#	Group
Primary Policy Holder Name	Date of Birth	
Secondary Insurance	Insurance Policy/ID#	Group
Secondary Policy Holder Name	Date of Birth	

SPECIMEN INFORMATION

REQUIRED

Sample Type

☐ Buccal Swab ☐ Extracted DNA

Sample Draw Date (mm/dd/yyyy)

...../...../.....

Shipping Instructions

- Label each specimen tube with the patient's full name and date of birth or patient's full name and collection date.
- To receive the specimen requirements and shipping guidelines, please send an email to - **info@minervalabs.health**

Send completed Requisition form with collected sample to:
1203 South White Chapel STE 150,

Southlake,Texas 76092

CLINICAL HISTORY

Indications for Testing ☐ Diagnostic ☐ Presymptomatic ☐ Family History ☐ Family Variant ☐ Other:

Age of Primary Diagnosis:

Previous genetic tests: ☐ Yes ☐ No

(If Yes, please specify the test and results)

Will Patient management be changed depending on the test results? ☐ Yes ☐ No

FAMILY HISTORY

☐ No Known Family History ☐ Pedigree Attached ☐ Adopted

Relationship	Maternal	Paternal	Relavant History	Age at Disgnosis
1	☐	☐		
2	☐	☐		
3	☐	☐		

CUSTOM PANEL (SELECT GENES) OR COMPREHENSIVE PANEL

REQUIRED

☐ PIK3CA	☐ SLC5A5	☐ PAX8	☐ TGFBI	☐ ATP1A2	☐ PLN	☐ IRAK1	☐ CST3
☐ TRH	☐ CACNA1A	☐ GLIS3	☐ TG	☐ HRAS	☐ TFR2	☐ G6PD	☐ CST1
☐ THRB	☐ PRKCG	☐ FOXE1	☐ THRA	☐ TTR	☐ SLC26A4	☐ SLC16A2	☐ CSTB
☐ C TNNB1	☐ HAMP	☐ SECISBP2	☐ TP53	☐ IYD	☐ TSHR	☐ IGSF1	☐ DUOX2
☐ KRAS	☐ SLC40A1	☐ GNAQ	☐ TSHB	☐ HFE	☐ NKX2-1	☐ TBL1X	☐ RET
☐ DUOX1	☐ TPO	☐ PLCG2	☐ NRAS	☐ ESR1	☐ MECP2	☐ IRS4	

COMMONLY USED ICD10 (DIAGNOSIS) CODES

please note, the icd-10 codes herein are solely for informational use. it is incumbent upon order practitioners to the diagnosis code that precisely justifies test conduct, regardless of its presence in the subsequent list.

Category - 1: ICD10 codes

- ☐ E06.0 Acute thyroiditis
- ☐ E06.1 Subacute thyroiditis
- ☐ E06.2 Chronic thyroiditis with transient thyrotoxicosis
- ☐ E06.3 Autoimmune thyroiditis
- ☐ E06.4 Drug-induced thyroiditis
- ☐ E06.5 Other chronic thyroiditis
- ☐ E06.9 Thyroiditis, unspecified
- ☐ E03.0 Congenital hypothyroidism with diffuse goiter
- ☐ E03.1 Congenital hypothyroidism without goiter
- ☐ E03.2 Hypothyroidism due to medicaments and other exogenous substances
- ☐ E03.3 Post-infectious hypothyroidism
- ☐ E03.4 Atrophy of thyroid (acquired)
- ☐ E03.5 Myxedema coma
- ☐ E03.8 Other specified hypothyroidism
- ☐ E03.9 Hypothyroidism, unspecified
- ☐ E01.0 Iodine-deficiency related diffuse (endemic) goiter
- ☐ E01.1 Iodine-deficiency related multinodular (endemic) goiter
- ☐ E01.2 Iodine-deficiency related (endemic) goiter, unspecified
- ☐ E01.8 Other iodine-deficiency related thyroid disorders and allied conditions
- ☐ E04.0 Nontoxic diffuse goiter
- ☐ E04.1 Nontoxic single thyroid nodule
- ☐ E04.2 Nontoxic multinodular goiter
- ☐ E04.8 Other specified nontoxic goiter
- ☐ E04.9 Nontoxic goiter, unspecified
- ☐ E05.00 Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
- ☐ E05.01 Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm
- ☐ E05.10 Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm
- ☐ E05.11 Thyrotoxicosis with toxic single thyroid nodule with thyrotoxic crisis or storm
- ☐ E05.20 Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm
- ☐ E05.21 Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm
- ☐ E05.30 Thyrotoxicosis from ectopic thyroid tissue without thyrotoxic crisis or storm
- ☐ E05.31 Thyrotoxicosis from ectopic thyroid tissue with thyrotoxic crisis or storm
- ☐ E05.40 Thyrotoxicosis factitia without thyrotoxic crisis or storm
- ☐ E05.41 Thyrotoxicosis factitia with thyrotoxic crisis or storm
- ☐ E05.80 Other thyrotoxicosis without thyrotoxic crisis or storm
- ☐ E05.81 Other thyrotoxicosis with thyrotoxic crisis or storm
- ☐ E05.90 Thyrotoxicosis, unspecified without thyrotoxic crisis or storm
- ☐ E05.91 Thyrotoxicosis, unspecified with thyrotoxic crisis or storm
- ☐ E07.0 Hypersecretion of calcitonin
- ☐ E07.1 Dyshormogenetic goiter
- ☐ E07.81 Sick-euthyroid syndrome
- ☐ E07.89 Other specified disorders of thyroid
- ☐ E07.9 Disorder of thyroid, unspecified
- ☐ E20.1 Pseudohypoparathyroidism
- ☐ Z85.8 Personal history of malignant neoplasms organs and systems
- ☐ D02.0 Carcinoma in situ of larynx
- ☐ D09.3 Carcinoma in situ of thyroid and other endocrine glands
- ☐ D14.1 Benign neoplasm of larynx

Category - 2: ICD10 codes

- ☐ C17.0 Malignant neoplasm of duodenum
- ☐ C17.1 Malignant neoplasm of jejunum
- ☐ C17.2 Malignant neoplasm of ileum
- ☐ C17.3 Meckel's diverticulum, malignant
- ☐ C17.8 Malignant neoplasm of overlapping sites of small intestine
- ☐ C17.9 Malignant neoplasm of small intestine, unspecified
- ☐ C18.0 Malignant neoplasm of cecum
- ☐ C18.1 Malignant neoplasm of appendix
- ☐ C18.2 Malignant neoplasm of ascending colon
- ☐ C18.3 Malignant neoplasm of hepatic flexure
- ☐ C18.4 Malignant neoplasm of transverse colon
- ☐ C18.5 Malignant neoplasm of splenic flexure
- ☐ C18.6 Malignant neoplasm of descending colon
- ☐ C18.7 Malignant neoplasm of sigmoid colon
- ☐ C18.8 Malignant neoplasm of overlapping sites of colon
- ☐ C18.9 Malignant neoplasm of colon, unspecified
- ☐ C19. Malignant neoplasm of rectosigmoid junction
- ☐ C20. Malignant neoplasm of rectum
- ☐ C21.0 Malignant neoplasm of anus, unspecified
- ☐ C21.1 Malignant neoplasm of anal canal
- ☐ C21.2 Malignant neoplasm of cloacogenic zone
- ☐ C21.8 Malignant neoplasm of overlapping of rectum, anus and anal canal
- ☐ C33 Malignant neoplasm of trachea
- ☐ C34.0 Malignant neoplasm of unspecified main bronchus
- ☐ C34.1 Malignant neoplasm of right main bronchus
- ☐ C34.2 Malignant neoplasm of left main bronchus
- ☐ C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung
- ☐ C34.11 Malignant neoplasm of upper lobe, right bronchus or lung
- ☐ C34.12 Malignant neoplasm of upper lobe, left bronchus or lung
- ☐ C34.2 Malignant neoplasm of middle lobe, bronchus or lung
- ☐ C34.30 Malignant neoplasm of lower lobe, bronchus or lung
- ☐ C34.31 Malignant neoplasm of lower lobe, right bronchus or lung
- ☐ C34.32 Malignant neoplasm of lower lobe, left bronchus or lung
- ☐ C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung
- ☐ C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung

- ☐ C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung
- ☐ C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung
- ☐ C34.91 Malignant neoplasm of unspecified part of right bronchus or lung
- ☐ C34.92 Malignant neoplasm of unspecified part of left bronchus or lung
- ☐ C38.4 Malignant neoplasm of pleura
- ☐ C45.0 Mesothelioma of pleura
- ☐ C45.1 Mesothelioma of peritoneum
- ☐ C48.1 Malignant neoplasm of specified parts of peritoneum
- ☐ C48.2 Malignant neoplasm of peritoneum, unspecified
- ☐ C48.8 Malignant neoplasm of overlapping retroperitoneum and peritoneum
- ☐ C54.0 Malignant neoplasm of isthmus uteri
- ☐ C54.1 Malignant neoplasm of endometrium
- ☐ C54.2 Malignant neoplasm of myometrium
- ☐ C54.3 Malignant neoplasm of fundus uteri
- ☐ C54.8 Malignant neoplasm of overlapping sites of corpus uteri
- ☐ C54.9 Malignant neoplasm of corpus uteri, unspecified
- ☐ C55 Malignant neoplasm of uterus, part unspecified
- ☐ C56.1 Malignant neoplasm of right ovary
- ☐ C56.2 Malignant neoplasm of left ovary
- ☐ C56.3 Malignant neoplasm of bilateral ovaries
- ☐ C56.9 Malignant neoplasm of unspecified ovary
- ☐ C57.00 Malignant neoplasm of unspecified fallopian tube
- ☐ C57.01 Malignant neoplasm of right fallopian tube
- ☐ C57.02 Malignant neoplasm of left fallopian tube
- ☐ C57.10 Malignant neoplasm of unspecified broad ligament
- ☐ C57.11 Malignant neoplasm of right broad ligament
- ☐ C57.12 Malignant neoplasm of left broad ligament
- ☐ C57.20 Malignant neoplasm of unspecified round ligament
- ☐ C57.21 Malignant neoplasm of right round ligament
- ☐ C57.22 Malignant neoplasm of left round ligament
- ☐ C57.3 Malignant neoplasm of parametrium
- ☐ C57.4 Malignant neoplasm of uterine adnexa, unspecified
- ☐ C73 Malignant neoplasm of thyroid gland
- ☐ C92.00 Acute myeloblastic leukemia, not having achieved remission
- ☐ C92.01 Acute myeloblastic leukemia, in remission
- ☐ C92.02 Acute myeloblastic leukemia, in relapse
- ☐ C92.10 Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
- ☐ C92.11 Chronic myeloid leukemia, BCR/ABL-positive, in remission
- ☐ C92.12 Chronic myeloid leukemia, BCR/ABL-positive, in relapse
- ☐ C92.40 Acute promyelocytic leukemia, not having achieved remission
- ☐ C92.41 Acute promyelocytic leukemia, in remission
- ☐ C92.42 Acute promyelocytic leukemia, in relapse
- ☐ C92.50 Acute myelomonocytic leukemia, not having achieved remission
- ☐ C92.51 Acute myelomonocytic leukemia, in remission
- ☐ C92.52 Acute myelomonocytic leukemia, in relapse
- ☐ C92.60 Acute myeloid leukemia with 11q23-abnormality not having achieved remission
- ☐ C92.61 Acute myeloid leukemia with 11q23-abnormality in remission
- ☐ C92.62 Acute myeloid leukemia with 11q23-abnormality in relapse
- ☐ C92.A0 Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
- ☐ C92.A1 Acute myeloid leukemia with multilineage dysplasia, in remission
- ☐ C92.A2 Acute myeloid leukemia with multilineage dysplasia, in relapse
- ☐ C93.10 Chronic myelomonocytic leukemia not having achieved remission
- ☐ C93.11 Chronic myelomonocytic leukemia, in remission
- ☐ C93.12 Chronic myelomonocytic leukemia, in relapse
- ☐ D34 Benign neoplasm of thyroid gland
- ☐ D44.0 Neoplasm of uncertain behavior of thyroid gland
- ☐ D44.2 Neoplasm of uncertain behavior of parathyroid gland
- ☐ D44.9 Neoplasm of uncertain behavior of unspecified endocrine gland
- ☐ D46.0 Refractory anemia without ring sideroblasts, so stated
- ☐ D46.1 Refractory anemia with ring sideroblasts
- ☐ D46.20 Refractory anemia with excess of blasts, unspecified
- ☐ D46.21 Refractory anemia with excess of blasts 1
- ☐ D46.22 Refractory anemia with excess of blasts 2
- ☐ D46.4 Refractory anemia, unspecified
- ☐ D46.9 Myelodysplastic syndrome, unspecified
- ☐ D46.A Refractory cytopenia with multilineage dysplasia
- ☐ D46.B Refractory cytopenia with multilineage dysplasia ring sideroblasts
- ☐ D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
- ☐ D46.Z Other myelodysplastic syndromes
- ☐ E01.0 Iodine-deficiency related diffuse (endemic) goiter
- ☐ E01.1 Iodine-deficiency related multinodular (endemic) goiter
- ☐ E01.2 Iodine-deficiency related (endemic) goiter, unspecified
- ☐ E04.0 Nontoxic diffuse goiter
- ☐ E04.1 Nontoxic single thyroid nodule
- ☐ E04. Nontoxic multinodular goiter
- ☐ E04.8 Other specified nontoxic goiter
- ☐ E04.9 Nontoxic goiter, unspecified
- ☐ Z85.030 Personal history of malignant carcinoid tumor of large intestine
- ☐ Z85.038 Personal history of other malignant neoplasm of large intestine
- ☐ Z85.040 Personal history of malignant carcinoid tumor of rectum
- ☐ Z85.048 Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus

Additional ICD Codes: _____

_____

PATIENT CONSENT

By signing this form, I acknowledge that the information provided by me is true and correct. I have read or have had read to me the **Minerva Labs** Informed Consent document at the end of this test requisition form, and understand the information regarding molecular genetics testing. For direct insurance billing: I authorize my insurance benefits to be paid directly to **Minerva Labs** and their affiliates, authorize **Minerva Labs** to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending **Minerva Labs** and their affiliates, money received from my health insurance company. I also give permission for my specimen and clinical information to be used in de-identified studies at **Minerva Labs** and their affiliates for publication, if appropriate. I have had the opportunity to ask questions about the testing, the procedure, the risks, and the alternatives. I authorize **Minerva Labs** and their affiliates to perform the testing as ordered.

Signature Date

Certificate of medical necessity, Consent, Test Authorization and Physician Signature

The individual signing this form, or their representative, hereby confirms their status as a licensed medical professional authorized to order genetic testing and confirms that the patient has provided informed consent for the testing and that it is medically necessary. They certify that any custom panel and/or ordered test(s) requested on this test requisition form are reasonable and medically necessary for the diagnosis and/or treatment of a disease, illness, impairment, symptom, syndrome, or disorder. They acknowledge that the test results may have an impact on the patient's medical management. The information provided on this form is accurate to the best of their knowledge. The signature on this form applies to the attached letter of medical necessity. If the insurance provider requests the laboratory to gather the medical necessity for any reason, the signer agrees to provide the Care Plan notes and Letter of Intent for this order.

Signature Date

INFORMED CONSENT

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

1. Positive: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
2. Negative: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
3. Variant of Uncertain Significance (VUS): A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
4. Unexpected Results: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes.

We may disclose this information to the ordering healthcare provider if it likely affects medical care.

Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information **Minerva Labs** used to interpret my results. Healthcare providers can contact **Minerva Labs** at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents.

Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that **Minerva Labs** will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.
2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.
To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information.
More information can be found at: www.genome.gov/10002077

INTERNATIONAL SAMPLES

If I reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my residence.

SAMPLE RETENTION After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. **Minerva Labs** will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made.

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and **Minerva Labs** will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. **Minerva Labs** will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this deidentified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. **Minerva Labs** shares this type of information with healthcare providers, scientists, and healthcare databases. **Minerva Labs** will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. **Minerva Labs** believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

- Applicable only for full exome sequencing and genome sequencing tests
- Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features. The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT?

All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES? The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS

Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified nor reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE

For insurance billing, I understand and authorize **Minerva Labs** to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to **Minerva Labs.**

I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by **Minerva Labs** as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by **Minerva Labs** on my behalf, I agree to endorse the insurance check and forward it to **Minerva Labs** within 30 days of receipt as payment towards **Minerva Labs** claim for services rendered.

If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by **Minerva Labs.** I further understand and agree that, if I fail to make payment for genetic testing, in accordance with the payment policies of **Minerva Labs**, my account may be turned over to an external collection agency for non-payment. I agree to pay any associated collection costs, including attorney fees. By my signature on the **Minerva Labs** Test Requisition Form or at the bottom of this form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider.

1203 South White Chapel Suite 150
Southlake, Texas 76092
Phone: +1 965-279-2091 | Email: info@minervalabs.health | Website: www.minervalabs.health